Sign In
Buy PACB
$1.45
-0.180 (-11.04%)
At Close: Jun 05, 2026
LOS ANGELES, CA / ACCESSWIRE / October 19, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Pacific Biosci
LOS ANGELES, CA / ACCESSWIRE / October 18, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Pacific Biosci
LOS ANGELES, CA / ACCESSWIRE / October 17, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Pacific Biosci
Pacific Biosciences of California (PACB) Stock Slides as Market Rises: Facts to Know Before You Trade
07:21pm, Wednesday, 16'th Oct 2024
In the latest trading session, Pacific Biosciences of California (PACB) closed at $2.06, marking a -1.9% move from the previous day.
Reasons to Retain PacBio Stock in Your Portfolio for Now
02:35pm, Tuesday, 15'th Oct 2024
PACB's strong product demand and continued focus on R&D raise optimism about the stock.
LOS ANGELES, CA / ACCESSWIRE / October 15, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Pacific Biosci
PacBio Shares Rise After NCCS Partnership for Cancer Genomics Research
12:27pm, Monday, 14'th Oct 2024
PACB partners with NCCS to enhance cancer research using the Onso short-read platform and Revio long-read sequencing, advancing precision oncology in Singapore and Asia.
LOS ANGELES, CA / ACCESSWIRE / October 14, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Pacific Biosci
LOS ANGELES, CA / ACCESSWIRE / October 13, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Pacific Biosci
Investors Are Encouraged To Join An Inquiry Into Pacific Biosciences of California Inc For Possible Securities Fraud
11:00am, Saturday, 12'th Oct 2024
LOS ANGELES, CA / ACCESSWIRE / October 12, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Pacific Biosci
LOS ANGELES, CA / ACCESSWIRE / October 11, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Pacific Biosci
PacBio Enters Cancer Genomics Research Collaboration in Singapore with Advanced Onso Sequencing
09:05am, Friday, 11'th Oct 2024
Groundbreaking collaboration to unlock the full potential of PacBio's Onso technology, accelerating breakthroughs in cancer genomics across Asia Groundbreaking collaboration to unlock the full potenti
PacBio to Report Third Quarter 2024 Financial Results on November 7, 2024
04:05pm, Thursday, 10'th Oct 2024
MENLO PARK, Calif., Oct. 10, 2024 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) announced today that it will hold its quarterly conference call to discuss its third quarter 2024 financial results on Thurs
Investors Are Encouraged To Join The Schall Law Firm's Inquiry Into Pacific Biosciences of California Inc For Possible Securities Fraud
11:00am, Thursday, 10'th Oct 2024
LOS ANGELES, CA / ACCESSWIRE / October 10, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Pacific Biosci
LOS ANGELES, CA / ACCESSWIRE / October 9, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Pacific Bioscie
